Dr. Leung Roland Ching Yu - Medical Oncology
Specialist in Medical Oncology
Highlights
- MCHK RegisteredVerified
- Specialist in Medical OncologyBachelor of Medicine and Bachelor of Surgery, The University of Edinburgh · Medical degree 1997
- InsuranceBeing compiled｜See details
About
Dr. Leung Roland Ching Yu is a registered Medical Oncology specialist in Hong Kong.
Education
Specialist in Medical Oncology
- Bachelor of Medicine and Bachelor of Surgery, The University of EdinburghBachelor of Medicine and Bachelor of Surgery, The University of Edinburgh1997
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Leung Roland Ching Yu? Claim page and update insurance →
FAQ
Is Dr. Leung Roland Ching Yu any good?
Dr. Leung Roland Ching Yu is a registered Medical Oncology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Leung Roland Ching Yu do?
Dr. Leung Roland Ching Yu practises in Medical Oncology.
Are you Dr. Leung Roland Ching Yu? Claim this page to update and manage.
ClaimResearch and publications
25 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis.Clinical breast cancer · 2026
- Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma.Frontiers in oncology · 2026
- Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study.Advances in therapy · 2025
- Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma.Biomedicines · 2025
- A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors.Investigational new drugs · 2025
- A step towards multimodality relief for painful hepatic cancer: the CCTG HE1 trial.Translational gastroenterology and hepatology · 2025
- Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.Oncology and therapy · 2024
- Consensus Statements on Precision Oncology in the China Greater Bay Area.JCO precision oncology · 2023
- Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?Hepatology communications · 2023
- Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2021
- Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.Cancers · 2021
- Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.Expert review of gastroenterology & hepatology · 2021
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
Elsewhere on the web
These links are matched automatically by the doctor's name and are not confirmed by the doctor. Names repeat in Hong Kong — open a link to check.
For reference only. Not medical advice. Read full disclaimer